drug · small molecule
patient view →elafibranor
Marketedupdated 2mo agoby Ipsen SA🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cholangitis and biliary liver cirrhosis and 7 investigational indications.
targets
Peroxisome proliferator-activated receptor alphaPeroxisome proliferator-activated receptor delta
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that